- Home
- LNTH vs CNTA Comparison
LNTH vs CNTA Comparison
Compare LNTH & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LNTH | CNTA |
|---|---|---|
| Founded | 1956 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.7B |
| IPO Year | 2015 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LNTH | CNTA |
|---|---|---|
| Price | $67.59 | $25.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $78.00 | $38.00 |
| AVG Volume (30 Days) | 788.1K | ★ 1.5M |
| Earning Date | 02-25-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.39 | N/A |
| Revenue | ★ $1,525,933,000.00 | $15,000,000.00 |
| Revenue This Year | $0.01 | N/A |
| Revenue Next Year | $0.26 | N/A |
| P/E Ratio | $28.21 | ★ N/A |
| Revenue Growth | 1.95 | ★ 118.88 |
| 52 Week Low | $47.25 | $9.60 |
| 52 Week High | $111.29 | $30.58 |
Technical Indicators
Market Signals| Indicator | LNTH | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 58.69 | 60.08 |
| Support Level | $63.37 | $21.50 |
| Resistance Level | $67.92 | $22.47 |
| Average True Range (ATR) | 2.06 | 1.08 |
| MACD | -0.37 | 0.38 |
| Stochastic Oscillator | 58.76 | 87.67 |
Price Performance
Historical ComparisonAbout LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.